Here at SpineX we are pushing the boundaries of
research to find the most effective solutions for
patients with neurological conditions.
Our SCONE™ device has received FDA Breakthrough Device Designation for the treatment of neurogenic bladder due to spinal cord injury, Multiple Sclerosis, and stroke. Our pivotal clinical trial is currently ongoing at multiple centers across the US and globally.
Our SCiP™ device has received FDA Breakthrough Device Designation for the treatment of movement disorders in Cerebral Palsy. We anticipate a multicenter pivotal trial to commence in H2 2023.
We are continuing to expand our indication pipeline including bowel and sexual function, spasticity, sensation, and cardiovascular function.
Our SCONE™ device has received FDA Breakthrough Device Designation for the treatment of neurogenic bladder due to spinal cord injury, Multiple Sclerosis, and stroke. Our pivotal clinical trial is currently ongoing at multiple centers across the US and globally.
Our SCiP™ device has received FDA Breakthrough Device Designation for the treatment of movement disorders in Cerebral Palsy. We anticipate a multicenter pivotal trial to commence in H2 2023.
We are continuing to expand our indication pipeline including bowel and sexual function, spasticity, sensation, and cardiovascular function.